Machine Learning Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm Business Wire Aug 16, 2023 New artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy Viz.ai, the leader in AI-powered…
Machine Learning Viz.ai Appoints Hypertrophic Cardiomyopathy Medical Advisory Board to Advance Innovation Business Wire May 8, 2023 Leading experts to shape the future of Viz.ai’s HCM strategy and platform Viz.ai, the leader in AI-powered disease detection and intelligent care…
Machine Learning Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of… Business Wire Mar 4, 2023 Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with…
Technology PicnicHealth Announces Engagement with Bristol Myers Squibb to Leverage Real-World Evidence AIT News Desk Nov 11, 2022 This engagement is designed to help Bristol Myers Squibb unlock new insights about long-term, real-world patient experiences within the…